Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...

Community members are launching into action to help fund medical bills for Carpinterian Lisa Burch, 61, who has Amyotrophic ...

Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.

Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...

Early in his career he devised a contraption capable of distinguishing certain mineral signatures underground, and he later took part in one of the high adventures of Canada’s storied mining history ...

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

People living with motor neuron disease (MND) will have more opportunities to participate in groundbreaking research, thanks ...

NLS Pharmaceutics (NLSP) announced that its CEO Alex Zwyer, has issued a letter to shareholders, which read in part, “Over ...